Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Non-cash Items (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Non-cash Items for 10 consecutive years, with $158000.0 as the latest value for Q4 2025.

  • Quarterly Non-cash Items fell 90.16% to $158000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $158000.0 through Dec 2025, down 90.16% year-over-year, with the annual reading at $158000.0 for FY2025, 90.16% down from the prior year.
  • Non-cash Items for Q4 2025 was $158000.0 at Rein Therapeutics, up from $153000.0 in the prior quarter.
  • The five-year high for Non-cash Items was $8.9 million in Q1 2024, with the low at $4000.0 in Q4 2021.
  • Average Non-cash Items over 5 years is $2.1 million, with a median of $1.7 million recorded in 2023.
  • The sharpest move saw Non-cash Items tumbled 99.83% in 2021, then skyrocketed 7120.52% in 2022.
  • Over 5 years, Non-cash Items stood at $4000.0 in 2021, then surged by 7120.52% to $288821.0 in 2022, then surged by 551.68% to $1.9 million in 2023, then fell by 14.73% to $1.6 million in 2024, then crashed by 90.16% to $158000.0 in 2025.
  • According to Business Quant data, Non-cash Items over the past three periods came in at $158000.0, $153000.0, and $2.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.